Hospital
VHS of Arrowhead, INC
VHS of Arrowhead, INC was paid $27.72M by Medicaid between Jan 2018 and Dec 2024, across 246 billing codes. Its largest line is 99284, emergency room visit (serious) — 24% of everything it billed.
33Billing provider infoVHS OF ARROWHEAD, INC
GLENDALE, AZ 85308
GLENDALE, AZ 85308
33aNPI1326022765assigned 11/30/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$27.72M
24GClaims790,362
24DCodes billed246
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#20 of 78
Median peer was paid$12.21M
This provider vs. median2.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 136,181 | $4.38M | |
| 2019 | 133,369 | $4.38M | |
| 2020 | 108,959 | $3.70M | |
| 2021 | 118,319 | $4.16M | |
| 2022 | 102,117 | $3.73M | |
| 2023 | 104,790 | $3.91M | |
| 2024incomplete | 86,627 | $3.46M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 31,088 | 27,910 | $6.60M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 26,746 | 24,527 | $4.76M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 19,210 | 17,218 | $4.55M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 10% | 5,295 | 4,900 | $2.80M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 6.0% | 4,099 | 3,763 | $1.66M |
| 58661 | 4.1% | 353 | 328 | $1.14M | |
| 59025 | Fetal non-stress test | 3.1% | 13,574 | 9,841 | $854K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.5% | 4,901 | 2,491 | $706K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.5% | 2,067 | 1,899 | $694K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 5,727 | 5,233 | $493K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.7% | 1,677 | 1,551 | $473K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 7,439 | 6,811 | $446K |
234 more codes
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.1% | 1,467 | $295K |
| 47562 | 1.0% | 85 | $285K | |
| G0378 | Hospital observation service, per hour | <1% | 8,479 | $273K |
| 58670 | <1% | 58 | $150K | |
| 52356 | <1% | 59 | $134K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 20,753 | $109K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 164 | $102K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 198 | $101K |
| 82805 | <1% | 1,131 | $83K | |
| 80053 | Comprehensive metabolic panel | <1% | 38,214 | $80K |
| C1781 | Mesh (implantable) | <1% | 715 | $73K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 750 | $64K |
| 93971 | <1% | 1,303 | $64K | |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | <1% | 498 | $63K |
| 93970 | <1% | 344 | $57K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,158 | $39K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 13 | $35K |
| 88307 | <1% | 735 | $34K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 727 | $33K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,624 | $29K |
| 97597 | <1% | 548 | $28K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,499 | $26K |
| 72131 | <1% | 99 | $25K | |
| 93458 | <1% | 28 | $24K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,071 | $22K |
| 50590 | <1% | 13 | $20K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,227 | $20K |
| 70498 | <1% | 59 | $18K | |
| 76818 | <1% | 941 | $18K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,227 | $15K |
| 84112 | <1% | 2,557 | $14K | |
| 96376 | <1% | 5,473 | $12K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,383 | $12K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,410 | $12K |
| 15271 | <1% | 38 | $11K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,587 | $10K |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 77 | $9K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 21,861 | $8K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 549 | $8K |
| 88342 | <1% | 528 | $7K | |
| 93312 | <1% | 45 | $6K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 950 | $6K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 44,286 | $6K |
| 93975 | <1% | 31 | $5K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 12 | $5K |
| 11045 | <1% | 256 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,681 | $4K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,924 | $4K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,151 | $4K |
| 93976 | <1% | 995 | $4K | |
| 70496 | <1% | 73 | $4K | |
| 73630 | <1% | 660 | $4K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,457 | $4K |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 1,044 | $4K |
| 71045 | Radiologic examination, chest; single view | <1% | 11,989 | $3K |
| 70486 | <1% | 68 | $3K | |
| 76801 | <1% | 1,924 | $3K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,782 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,828 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,209 | $3K |
| 74018 | <1% | 826 | $2K | |
| 84484 | <1% | 13,135 | $2K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,194 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,294 | $2K |
| 73130 | <1% | 315 | $2K | |
| 88304 | <1% | 2,212 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 25,109 | $2K |
| 86850 | <1% | 4,265 | $2K | |
| 83690 | <1% | 10,450 | $2K | |
| 84703 | <1% | 7,452 | $2K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 161 | $2K |
| 81025 | <1% | 6,350 | $2K | |
| 73564 | <1% | 211 | $1K | |
| 84702 | <1% | 2,912 | $1K | |
| 87186 | <1% | 3,067 | $1K | |
| 73562 | <1% | 241 | $1K | |
| 85379 | <1% | 3,008 | $1K | |
| 76830 | Ultrasound, transvaginal | <1% | 351 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,250 | $1K |
| 81001 | <1% | 24,127 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,687 | $958.15 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,038 | $883.97 |
| 81003 | <1% | 10,324 | $801.97 | |
| 83735 | <1% | 7,492 | $774.23 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,299 | $764.21 |
| 85027 | <1% | 6,353 | $649.25 | |
| 36600 | <1% | 598 | $647.95 | |
| 73110 | <1% | 219 | $623.09 | |
| 82731 | <1% | 1,034 | $611.30 | |
| 83880 | <1% | 2,833 | $557.21 | |
| 87430 | <1% | 1,553 | $529.55 | |
| 73030 | <1% | 773 | $527.33 | |
| 87206 | <1% | 108 | $482.97 | |
| 86635 | <1% | 14 | $458.75 | |
| 87400 | <1% | 2,208 | $396.80 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 12,819 | $393.48 |
| 93017 | <1% | 127 | $393.48 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,093 | $389.66 |
| 87088 | <1% | 12,325 | $351.21 | |
| 80061 | Lipid panel | <1% | 1,348 | $322.64 |
| 85730 | <1% | 5,141 | $285.37 | |
| 88341 | <1% | 31 | $283.76 | |
| 85610 | <1% | 8,760 | $274.37 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 606 | $243.14 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,859 | $230.77 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 619 | $230.49 |
| 83605 | <1% | 3,101 | $211.54 | |
| 82962 | <1% | 10,805 | $201.16 | |
| 76775 | <1% | 52 | $195.75 | |
| 29515 | <1% | 27 | $194.52 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,842 | $176.79 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 6,379 | $172.14 |
| 90715 | <1% | 389 | $171.65 | |
| 80076 | <1% | 340 | $166.79 | |
| 87077 | <1% | 2,257 | $158.93 | |
| 84100 | <1% | 1,632 | $130.11 | |
| 73610 | <1% | 559 | $121.65 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,478 | $120.82 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,645 | $117.85 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,726 | $117.50 |
| J2704 | Injection, propofol, 10 mg | <1% | 14,244 | $115.60 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,185 | $113.93 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 919 | $112.74 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 11,687 | $104.90 |
| 86901 | <1% | 5,766 | $100.27 | |
| 87081 | <1% | 1,390 | $90.92 | |
| 87040 | <1% | 1,694 | $90.91 | |
| 82550 | <1% | 1,459 | $71.84 | |
| 86900 | <1% | 5,768 | $71.47 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,900 | $67.54 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 16,666 | $64.86 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 891 | $64.37 |
| 87147 | <1% | 583 | $60.91 | |
| 87210 | <1% | 1,946 | $59.63 | |
| 99001 | <1% | 2,890 | $58.82 | |
| 72040 | <1% | 26 | $49.87 | |
| 87205 | <1% | 1,769 | $49.46 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,206 | $43.45 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,002 | $32.35 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 392 | $31.99 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 190 | $29.39 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 3,033 | $26.87 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 307 | $25.42 |
| 84550 | <1% | 1,957 | $24.57 | |
| 83615 | <1% | 1,867 | $24.19 | |
| 87420 | <1% | 258 | $23.94 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 882 | $22.04 |
| 87070 | <1% | 1,489 | $21.64 | |
| 82570 | <1% | 1,233 | $20.03 | |
| 84156 | <1% | 1,321 | $19.49 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 118 | $16.86 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,140 | $15.18 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 269 | $14.48 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,179 | $12.73 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 91 | $9.40 |
| 82150 | <1% | 55 | $5.18 | |
| 72100 | <1% | 345 | $4.92 | |
| 84132 | <1% | 31 | $3.44 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 647 | $2.55 |
| 85651 | <1% | 111 | $2.37 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 3,334 | $1.73 |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,089 | $1.62 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 573 | $0.94 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,416 | $0.59 |
| J3490 | Unclassified drugs | 0% | 3,549 | $0.00 |
| C1769 | Guide wire | 0% | 2,961 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 497 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 515 | $0.00 |
| 74022 | 0% | 67 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 25 | $0.00 |
| 88300 | 0% | 148 | $0.00 | |
| J3590 | Unclassified biologics | 0% | 16 | $0.00 |
| A9270 | Non-covered item or service | 0% | 9,668 | $0.00 |
| 74420 | 0% | 399 | $0.00 | |
| J7999 | Compounded drug, not otherwise classified | 0% | 154 | $0.00 |
| A9150 | Non-prescription drugs | 0% | 269 | $0.00 |
| A4217 | Sterile water/saline, 500 ml | 0% | 57 | $0.00 |
| 73502 | 0% | 18 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 390 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 215 | $0.00 |
| 86140 | 0% | 59 | $0.00 | |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | 0% | 219 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 63 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 17 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 72 | $0.00 |
| 85018 | 0% | 12 | $0.00 | |
| 87116 | 0% | 113 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 42 | $0.00 |
| J2305 | Injection, nitroglycerin, 5 mg | 0% | 12 | $0.00 |
| 82270 | 0% | 13 | $0.00 | |
| 12001 | 0% | 42 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 130 | $0.00 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 0% | 26 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 28 | $0.00 |
| 90686 | 0% | 14 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 14 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 28 | $0.00 |
| 82360 | 0% | 13 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 417 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 2,097 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 328 | $0.00 |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 265 | $0.00 |
| 10060 | 0% | 25 | $0.00 | |
| 88302 | 0% | 563 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 86 | $0.00 |
| 88112 | 0% | 110 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 1,015 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 1,015 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 313 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 455 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 549 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 164 | $0.00 |
| 29125 | 0% | 92 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 29 | $0.00 |
| 85384 | 0% | 86 | $0.00 | |
| 73590 | 0% | 13 | $0.00 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 227 | $0.00 |
| 82365 | 0% | 70 | $0.00 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 0% | 42 | $0.00 |
| 89051 | 0% | 37 | $0.00 | |
| 85460 | 0% | 12 | $0.00 | |
| 87102 | 0% | 86 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 14 | $0.00 |
| 85347 | 0% | 42 | $0.00 | |
| 76937 | 0% | 97 | $0.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 58 | $0.00 |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | 0% | 35 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 48 | $0.00 |
| 84439 | 0% | 42 | $0.00 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 16 | $0.00 |
| 82565 | 0% | 25 | $0.00 | |
| C1729 | Catheter, drainage | 0% | 47 | $0.00 |
| 93325 | 0% | 31 | $0.00 | |
| 12011 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYOUNG, SHALEN (CFO)
| Provider | Location | Paid |
|---|---|---|
| VHS of Arrowhead, INC. | Phoenix, AZ | $5.21M |
| VHS of Arrowhead, INC. | Surprise, AZ | $4.22M |
| VHS of Arrowhead, INC. | Peoria, AZ | $2.25M |
| VHS of Arrowhead INC | Glendale, AZ | $865.07 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.